Société Française
de Thérapie Cellulaire
et Génique
SFTCG

2024 Workshop on Gene Editing & Cell Therapy

Nantes | 21 & 22 March 2024

PROGRAMME

Thursday 21 March: SFTCG Academy

12:00-13:00	**Registration and light lunch**
13:00-14:00	**Mentoring** Chair: **Els Verhoeyen,** *University of Nice* **INV01 Zoltan Ivics**, *Paul Ehrlich Institute, Langen* Digging in the Dirt: How Archeogenetics and Synthetic Biology Impacted Gene Therapy
14:00-15:30	**Oral presentations from students** (10 minute presentation and 20 minutes for questions and mentoring) Chairs: **Sophie Gomez,** *CRCL, Lyon*; **Capucine Trollet,** *Sorbonne University - Institut de Myologie*; **Els Verhoeyen,** *University of Nice* **OR01 Clémence Lièvre,** *TaRGeT, Nantes* Skeletal muscle organoids for preclinical gene therapy with recombinant AAV vectors **OR02 Clément Morival**, *TaRGeT, Nantes* Modelling Stargardt disease using three-dimensional retinal organoids **OR03 Carine Bourdais**, *IRBM, Montpellier* Combined cellular and gene therapy to treat primary ciliary dyskinesia
15:30-16:00	**Coffee Break**
16:00-18:30	**Oral presentations from students** (10 minute presentation and 20 minutes for questions and mentoring) Chairs: **Olivier Négre,** *Smart Immune, Paris*; **Françoise Piguet,** *TIDU GENOV, ICM, Paris* **OR05 Manon Lucas**, *TaRGeT, Nantes* High systemic dosing of AAV9 vectors: a relevant rat model to study the impact of vector immunogenicity in the liver **OR06 Laurie Lacombe**, *Généthon Evry* NHEJ inhibition increases homology-mediated AAV integration in hematopoietic cells **OR07 Jean Baptiste Ducloyer**, *TaRGeT, Nantes* Study of retinal microglial cells after sub-retinal injection of recombinant AAV in pigs **OR08 Marie Esnard**, *GEPEA – St Nazaire / TaRGeT, Nantes* Development of an AAV bioproduction technological platform in microalgae

Société Française de Thérapie Cellulaire et Génique
SFTCG

Friday 22 March: Theme Day

Thematic morning on gene editing

08:00-09:00	**Registration**
09:00-10:30	**Session 1** (10 minute presentation and 5 minutes for questions) Chairs: **François Moreau Gaudry,** *Equipe Biothérapie INSERM U1035, Université Bordeaux*; **Caroline Le Guiner,** *Nantes Université, CHU de Nantes, INSERM TaRGet Lab* **INV02 Carine Giovannangeli,** *Département AVIV, MNHN, CNRS UMR7196, INSERM U1154, Paris* **INV03 Annarita Miccio**, *Institut Imagine* Genome editing approaches for hematopoietic disorders **OR09 Paloma Navas Navarro**, *Généthon Evry* Treatment of myotonic dystrophy type 1 with CRISPR/Cas9 **OR10 Margaux Melka**, *Institut des Neurosciences de Grenoble* Mutation independent CRISPR/Cas9-induced allele deletion results in vitro in a functional benefit for dominant RYR1 mutation
10:30-11:00	**Coffee Break**
11:00-12:30	**Session 2** (10 minute presentation and 5 minutes for questions) Chairs: **Mario Amendola,** *INTEGRARE UMR951, Genethon, Evry*; **Matthias Titeux,** *Institut Imagine, Paris* **INV04 Maria Silvia Roman Azcona**, *University of Freiburg* Epigenome editing of immune checkpoints in CAR T cells **INV05 François Moreau Gaudry**, *University of Bordeaux* Genotoxicity risk induced by CRISPR-Cas9: understanding and preventing it **OR11 Juliette Varin**, *TaRGeT, Nantes* Homology-independent targeted integration (HITI) as possible treatment for Stargardt disease **OR12 Hugo Malki**, *Institut de la Vision, Paris* Delivery of Cas9 ribonucleoprotein to the retina of mice with Retinitis pigmentosa
12:30-14:00	**Lunch**

Thematic afternoon on cell therapy

14:00-15:30	**Session 3** (10 minute presentation and 5 minutes for questions) Chairs: **Christelle Monville,** *INSERM/UEVE UMR 861, I-STEM, AFM, Corbeil-Essonnes*; **Leila Maouche Chrétien,** *INSERM U 1163 / CNRS ERL 8254, Institut IMAGINE* **INV08 Philippe Menasché**, *Université Paris Cité* Cell therapy for cardiac diseases: successes and remaining challenges **INV09 Karl Rouger**, *PanTher - INRAe, ONIRIS, UMR 703 – Nantes* Muscle repair potential of adult stem cells through different modes of action **OR13 Isabelle Prost**, *Promega, France* New technologies for CAR-T characterization and potency testing **OR14 Allwyn Pereira**, *TaRGeT, Nantes* Multiomic analyses reveals epigenome remodelling and transcriptional co-factors as critical determinants for neuronal cell therapy
15:30-16:00	**Coffee Break**

16:00-17:30	**Session 4** (10 minute presentation and 5 minutes for questions) Chairs: **Oumeya Adjali,** *TaRGeT - INSERM UMR 1089, IRS 2 - Nantes Biotech*; **Emmanuel Payen,** *CEA, Fontenay aux Roses* **INV11 Jérémie Martinet**, *Rouen University* Irradiation as an adjuvant for CAR-T cell therapy **INV12 Vasco Meneghini**, *Hospital San Raffaele, Milano* Tackling neurodegeneration with neural stem and progenitor cells **OR15 Camille Le Guen**, *CHU Nantes* Can academic structures improve access to CAR-T cells?
17:30	**Closing**

WITH THANKS TO OUR EVENT SPONSOR

GENETHON
CURE THROUGH INNOVATION